Streetbeat News

BIIB

Biogen Inc.

https://www.biogen.com

Industry

Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Open

165.46

Mkt cap

23B

Volume

1.9M

High

166.34

P/E Ratio

14.54

52-wk high

268.30

Low

159.60

Div yield

N/A

52-wk low

159.60

Eisai and Biogen announced that the FDA has accepted Eisai's Supplemental Biologics License Application for LEQEMBI IV maintenance dosing to treat early Alzheimer's disease. The PDUFA action date is set for January 25, 2025.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:10 am

Biogen's short interest has risen by 10.25%, with 3.48 million shares sold short, representing 2.69% of its float. This is lower than the peer group average of 5.62%. It would take traders 3.34 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

June 07, 2024 | 3:15 pm

RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen (NASDAQ:BIIB) and maintained a price target of $317.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 2:36 pm

Biogen Inc. (NASDAQ:BIIB) shares surged after announcing a partnership with Delta Flight Products, a subsidiary of Delta Air Lines (NYSE:DAL), to enhance air travel accessibility for passengers with reduced mobility. The collaboration aims to develop innovative solutions, including a new airplane seat prototype that allows passengers to remain in their wheelchairs during flights.

Portfolio Pulse from Vaishali Prayag

June 03, 2024 | 6:43 pm

Biogen shares are trading higher following the announcement of a collaboration with Delta Air Lines to enhance flying experiences for passengers with reduced mobility.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:20 pm

Biogen Inc. (NASDAQ: BIIB) and Delta Flight Products, a subsidiary of Delta Air Lines, announced a collaboration to enhance air travel for passengers with reduced mobility. This initiative aims to improve the flying experience for approximately 5.5 million wheelchair users in the U.S.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:37 am

The European Commission has granted marketing authorization for Biogen's Qalsody (tofersen) for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene. This is the first treatment in the EU targeting a genetic cause of ALS. Despite the Phase 3 VALOR study showing numerical but not statistically significant efficacy, Qalsody has shown a significant reduction in neurofilament light chain levels. Biogen licensed Qalsody from Ionis Pharmaceuticals.

Portfolio Pulse from Vandana Singh

May 31, 2024 | 2:25 pm

Biogen has received marketing authorization from the European Commission for QALSODY, a treatment for SOD1-ALS, a rare and fatal genetic form of ALS. This is Biogen's third rare disease therapy approved in the EU, highlighting their commitment to addressing high unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:52 pm

RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen (NASDAQ:BIIB) and maintained a price target of $317.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 1:59 pm

Coya Therapeutics Inc (NASDAQ:COYA), a clinical-stage biotech company, has seen its shares rise by 70% since its IPO in December 2022. The company focuses on developing treatments for neurodegenerative and inflammatory diseases using regulatory T cells (Tregs). CEO Howard Berman highlighted the company's shift towards combination therapies and biologics, similar to approaches in cancer and viral disease treatments. Coya's lead program, COYA 302, is being developed for conditions like ALS, FTD, Parkinson's, and Alzheimer's. The company plans to file an FDA IND in 2Q24 and start a Phase 2 trial for ALS. Despite a recent 2.9% drop in share price, the company received a $5 million investment from the Alzheimer's Drug Discovery Foundation.

Portfolio Pulse from Vandana Singh

May 27, 2024 | 1:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.